Title: Atti del 52° Congresso Nazionale: Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (SItI) Document date: 2019_10_15
ID: jkke8ije_683
Snippet: Testing mCRC patients for RAS status and administering anti-EGFR therapy only to patients with RAS wild-type tumors is a more cost-effective strategy than treating all patients without testing. The treatment of mCRC is becoming more personalized, which is essential to avoid inappropriate therapy and unnecessary high healthcare costs. The economic evaluations, although of good quality, do not fully adhere to international recommendations regarding.....
Document: Testing mCRC patients for RAS status and administering anti-EGFR therapy only to patients with RAS wild-type tumors is a more cost-effective strategy than treating all patients without testing. The treatment of mCRC is becoming more personalized, which is essential to avoid inappropriate therapy and unnecessary high healthcare costs. The economic evaluations, although of good quality, do not fully adhere to international recommendations regarding the assessment of mutational status prior to therapy with biological agents. Future economic assessments should take into account NRAS mutation status and other parameters that reflect the real world, such as toxicity of biological agents, genetic test sensitivity and specificity. The impact of industry sponsorship of economic evaluations on pharmacogenetic tests needs further investigation.
Search related documents:
Co phrase search for related documents- anti egfr therapy and mcrc treatment: 1
- anti egfr therapy and mutation status: 1, 2
- anti egfr therapy and mutational status: 1
- anti egfr therapy and wild type: 1, 2, 3
- biological agent and cost effective strategy: 1
- biological agent and economic evaluation: 1
- biological agent and real world: 1
- biological agent and wild type: 1
- cost effective strategy and economic evaluation: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date